Sale!

CD79A Gene Agammaglobulinemia Type 3 Autosomal Recessive NGS Genetic DNA Test

Original price was: $700.Current price is: $500.

-29%

The CD79A Gene Agammaglobulinemia Type 3 Autosomal Recessive NGS Genetic DNA Test is a cutting-edge diagnostic tool that identifies mutations in the CD79A gene responsible for agammaglobulinemia type 3, a rare inherited immune deficiency disorder. This comprehensive test utilizes next-generation sequencing technology to provide precise genetic analysis, enabling early detection and personalized treatment strategies. Patients with recurrent infections, low antibody levels, or family history of immune disorders benefit from this advanced genetic screening. The test costs $500 USD and provides critical insights for hematologists and immunologists to develop targeted therapeutic approaches. Results are typically available within 3-4 weeks, offering valuable information for family planning and genetic counseling.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

CD79A Gene Agammaglobulinemia Type 3 Autosomal Recessive NGS Genetic DNA Test

Comprehensive Genetic Testing for Immune System Disorders

The CD79A Gene Agammaglobulinemia Type 3 Autosomal Recessive NGS Genetic DNA Test represents a breakthrough in molecular diagnostics for inherited immune deficiencies. This advanced genetic screening utilizes next-generation sequencing technology to detect mutations in the CD79A gene, which plays a crucial role in B-cell development and antibody production. Agammaglobulinemia type 3 is a rare autosomal recessive disorder characterized by the absence or severe reduction of immunoglobulins, leaving patients vulnerable to recurrent infections and autoimmune complications.

What This Test Measures and Detects

This sophisticated genetic analysis specifically targets the CD79A gene located on chromosome 19q13.2, which encodes the immunoglobulin-associated beta chain essential for B-cell receptor signaling. The test identifies:

  • Pathogenic variants and mutations in the CD79A gene
  • Single nucleotide polymorphisms (SNPs) affecting protein function
  • Insertions, deletions, and frameshift mutations
  • Copy number variations impacting gene expression
  • Autosomal recessive inheritance patterns

Who Should Consider This Genetic Test

This comprehensive genetic screening is recommended for individuals presenting with:

  • Recurrent bacterial infections, particularly respiratory and gastrointestinal
  • Severely reduced or absent serum immunoglobulins
  • Family history of agammaglobulinemia or immune deficiencies
  • Unexplained failure to thrive in infants and children
  • Autoimmune manifestations alongside immune deficiency
  • Consanguineous parentage with immune disorder concerns
  • Previous inconclusive immune workup results

Clinical Benefits of CD79A Genetic Testing

Undergoing this advanced genetic analysis provides numerous clinical advantages:

  • Accurate Diagnosis: Confirms agammaglobulinemia type 3 with molecular precision
  • Personalized Treatment: Enables targeted immunoglobulin replacement therapy
  • Family Planning: Provides crucial information for genetic counseling and reproductive decisions
  • Early Intervention: Facilitates prompt treatment initiation to prevent complications
  • Prognostic Insights: Helps predict disease progression and management requirements
  • Research Contribution: Advances understanding of rare immune disorders

Understanding Your Test Results

Our comprehensive genetic report provides detailed interpretation of your CD79A gene analysis:

  • Positive Result: Identifies pathogenic mutations confirming agammaglobulinemia type 3 diagnosis
  • Negative Result: No CD79A mutations detected, suggesting alternative causes for immune deficiency
  • Variant of Uncertain Significance: Identifies genetic changes requiring further clinical correlation
  • Carrier Status: Detects heterozygous mutations in asymptomatic individuals

All results include detailed clinical implications and recommendations for follow-up care with hematology and immunology specialists.

Test Pricing and Availability

Test Name Discount Price Regular Price
CD79A Gene Agammaglobulinemia Type 3 Autosomal Recessive NGS Genetic DNA Test $500 USD $700 USD

Nationwide Testing Availability

We proudly offer comprehensive genetic testing services across the United States with convenient locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more cities. Our state-of-the-art laboratories ensure consistent, high-quality results regardless of your location.

Sample Collection and Processing

This test requires one of the following sample types:

  • Blood sample collected by trained phlebotomists
  • Extracted DNA from previous genetic testing
  • One drop of blood on FTA card for convenient at-home collection

Turnaround Time: 3 to 4 weeks
Pre-test Requirements: Clinical history documentation and genetic counseling session to create detailed family pedigree chart

Take Control of Your Genetic Health Today

Don’t let uncertainty about immune disorders compromise your health and quality of life. Our CD79A genetic test provides the clarity needed for informed medical decisions and personalized treatment strategies. With our discounted price of $500 USD and nationwide availability, advanced genetic testing has never been more accessible.

Call or WhatsApp us today at +1(267) 388-9828 to schedule your genetic counseling session and book your CD79A Gene Agammaglobulinemia Type 3 Autosomal Recessive NGS Genetic DNA Test. Our dedicated genetic specialists are ready to guide you through every step of the testing process and help you understand your results for better health outcomes.